PP446 - HIGH‑PROTEIN HMB ORAL NUTRITIONAL SUPPLEMENTATION IMPROVES OUTCOMES IN PATIENTS WITH HIGH SYSTEMIC INFLAMMATION AT BASELINE: A SECONDARY ANALYSIS OF THE NOURISH TRIAL

PP446

HIGH‑PROTEIN HMB ORAL NUTRITIONAL SUPPLEMENTATION IMPROVES OUTCOMES IN PATIENTS WITH HIGH SYSTEMIC INFLAMMATION AT BASELINE: A SECONDARY ANALYSIS OF THE NOURISH TRIAL

G. Guzman Rolo^1,*, G. Baggs², L. Olivier³, A. Martin Aguilar¹, M. Camprubi Robles⁴, S. L. Pereira², R. Hegazi²

¹Abbott Laboratories, Madrid, Spain, ²Abbott Laboratories, Columbus, United States, ³Abbott Laboratories, Maidenhead, United Kingdom, ⁴Abbott Laboratories, Granada, Spain

Rationale: Disease-related inflammation has been reported to reduce the benefits of nutrition therapy. This study examined whether baseline inflammatory status, using C‑reactive protein (CRP) as a surrogate, influenced the effect of a specialized high‑protein β‑hydroxy‑β‑methylbutyrate oral nutritional supplement (HP‑HMB ONS) on clinical outcomes in hospitalized older patients with malnutrition.

Methods: This is a secondary analysis of the multicentre NOURISH trial (2012–2014), a prospective, randomized, double-blind, placebo-controlled study of 652 US adults ≥65 years with malnutrition. Patients received HP‑HMB ONS or placebo during hospitalization and for 90 days post‑discharge. The primary composite endpoint was 90-day post-discharge death or nonelective readmission. Baseline CRP was categorized as low (<10 mg/L), moderate (10–100 mg/L), or high (>100 mg/L). Outcomes included survival without readmission, readmission, and handgrip strength (HGS).

Results: Among 104 patients with high baseline CRP (>100 mg/L), those receiving HP‑HMB ONS (n=59) had higher odds of being alive and not readmitted at day 90 (OR 6.1; 95% CI 1.92–19.33; p=0.002) day 60 (OR=5.26, 95% CI: (1.65, 16.76); p=0.005) and day 30 (OR=4.15, 95% CI: (1.29,13.38); p=0.017) and higher odds of improved HGS at day 30 (OR 4.1; 95% CI 1.2–14.1; p=0.027) compared with placebo (n=45). HP‑HMB ONS was also associated with lower odds of readmission at day 90 (OR 0.26; 95% CI 0.08–0.85; p=0.026) and a trend toward lower mortality (OR 0.14; 95% CI 0.02–1.20; p=0.074).

Conclusion: In hospitalized older patients with high systemic inflammation, early HP‑HMB ONS use was associated with improved odds of survival without readmission and functional strength, supporting HP-HMB ONS use in high‑risk populations.

Disclosure of Interest: G. Guzman Rolo Other: Employee of Abbott Laboratories. , G. Baggs Other: Employee of Abbott Laboratories. , L. Olivier Other: Employee of Abbott Laboratories. , A. Martin Aguilar Other: Employee of Abbott Laboratories. , M. Camprubi Robles Other: Employee of Abbott Laboratories. , S. Pereira Other: Employee of Abbott Laboratories. , R. Hegazi Other: Employee of Abbott Laboratories.